Rare diseases
Investigational molecules
Locations
Ul. Strzalowska 22, 71-730 Szczecin, Poland
Zachodniopomorskie Centrum Onkologii in Szczecin, Poland specialises in clinical trials of conditions such as Hormone receptor positive HER2 negative breast cancer, Breast cancer, Malignant melanoma, Hormone-refractory prostate cancer, and other specialisations. This site conducts important research.
The medical center is at the forefront of breast cancer research, focusing on innovative treatment combinations and targeted therapies. The ongoing studies explore the efficacy of combining capivasertib with CDK4/6 inhibitors and fulvestrant for advanced HR+/HER2- breast cancer, aiming to improve progression-free survival (PFS) in various patient populations.
These studies contribute to the development of personalized medicine approaches, enhancing treatment outcomes for patients with specific genetic profiles.
Our center is pioneering research in non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), focusing on novel therapeutic agents like durvalumab. The trials aim to provide continuous treatment options for patients who benefit from previous studies, ensuring safety and tolerability while exploring new frontiers in lung cancer therapy.
These efforts are crucial in advancing the understanding of lung cancer biology and improving long-term patient outcomes.
The center is actively engaged in cutting-edge research for melanoma and other skin cancers, investigating the efficacy of novel agents like BNT111 and cemiplimab. These studies aim to enhance the objective response rate (ORR) in patients with late-stage skin cancer, offering hope for those unresponsive to conventional treatments.
By exploring innovative treatment modalities, the center is contributing to the development of more effective therapies for skin cancer patients.
Our institution is advancing the field of gastrointestinal cancers through research on gastric cancer and gastroesophageal junction adenocarcinoma. The focus is on evaluating the novel agent AZD0901 in comparison to standard treatments, particularly in patients with high levels of Claudin18.2.
This research is pivotal in identifying superior treatment options and improving survival rates for patients with advanced gastrointestinal cancers.
Clinical trials currently enrolling participants at this site.
PolandPolandPolandPolandPolandPolandPolandPolandPolandPolandPolandPolandGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
